Process R & D. The Noranda Process = Recherche et développement des procédés. Le procédé NorandaTARASSOFF, P.Metallurgical transactions. B, Process metallurgy. 1984, Vol 15, Num 3, pp 411-433, issn 0360-2141Article

CURRENT DISTRIBUTION AND RESISTANCES IN COPPER REFINERY TANKHOUSE CELLSMACKEY PJ; TARASSOFF P; LEMELIN G et al.1975; INSTIT. MING METALLURGY, BULL., TRANS.; G.B.; DA. 1975; VOL. 84; NO 820; PP. 42-48; BIBL. 22 REF.Article

THE NORANDA PROCESSTHEMELIS NJ; MCKERROW GC; TARASSOFF P et al.1972; J. METALS; U.S.A.; DA. 1972; VOL. 24; NO 4; PP. 25-32; BIBL. 7 REF.Serial Issue

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineGRUNWALD, R; ABBRUZZESE, J. L; TARASSOFF, P et al.Cancer chemotherapy and pharmacology. 1991, Vol 27, Num 4, pp 258-262, issn 0344-5704, 5 p.Article

A phase I clinical, phasma, and cellular pharmacology study of gemcitabineABBRUZZESE, J. L; GRUNEWALD, R; PLUNKETT, W et al.Journal of clinical oncology. 1991, Vol 9, Num 3, pp 491-498, issn 0732-183XArticle

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (gemcitabine) administration in leukemiaGRUNEWALD, R; KANTARJIAN, H; KEATING, M. J et al.Cancer research (Baltimore). 1990, Vol 50, Num 21, pp 6823-6826, issn 0008-5472, 4 p.Article

Improvements in survival and Clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : A randomized trialBURRIS, H. A; MOORE, M. J; NELSON, R et al.Journal of clinical oncology. 1997, Vol 15, Num 6, pp 2403-2413, issn 0732-183XArticle

Maximum-tolerated dose defined for single-agent gemcitabine : A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancerFOSSELLA, F. V; LIPPMAN, S. M; WAUN KI HONG et al.Journal of clinical oncology. 1997, Vol 15, Num 1, pp 310-316, issn 0732-183XArticle

Phase II study of gemcitabine in advanced colorectal adenocarcinomaMOORE, D. F; PAZDUR, R; DAUGHERTY, K et al.Investigational new drugs. 1992, Vol 10, Num 4, pp 323-325, issn 0167-6997Article

Phase II trial of gemcitabine in patients with advanced gastric cancerCHRISTMAN, K; KELSEN, D; SALTZ, L et al.Cancer. 1994, Vol 73, Num 1, pp 5-7, issn 0008-543XArticle

Pyridoxal phosphate as an antisickling agent in vitroKARK, J. A; TARASSOFF, P. G; BONGIOVANNI, R et al.The Journal of clinical investigation. 1983, Vol 71, Num 5, pp 1224-1229, issn 0021-9738Article

Successful renal transplantation for Epstein syndromeALVING, B. M; TARASSOFF, P. G; MOORE, J. JR et al.American journal of hematology. 1986, Vol 21, Num 1, pp 111-113, issn 0361-8609Article

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreasCASPER, E. S; GREEN, M. R; KELSEN, D. P et al.Investigational new drugs. 1994, Vol 12, Num 1, pp 29-34, issn 0167-6997Article

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerROTHENBERG, M. L; MOORE, M. J; STORNIOLO, A.-M et al.Annals of oncology. 1996, Vol 7, Num 4, pp 347-354, issn 0923-7534, 7 p.Article